Studies describing SARS-CoV-2 immune responses following mRNA vaccination in hematology malignancy (HM) patients are virtually non-existent. We measured SARS-CoV-2 IgG production in 67 HM patients who received 2 mRNA vaccine doses. We found that 46% of HM patients did not produce antibodies and were therefore vaccine non-responders. Patients with B-cell CLL were at a particularly high risk, as…
Marwan Fakih (Duarte, United States of America) We have previously reported significant differences between the tumor immune microenvironm ent (TIME) of primary colorectal cancer (CRC-P)…
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
This cross-sectional study examines the prevalence of germline findings in patients undergoing tumor/normal matched sequencing among cancer types lacking guidelines.
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications…
3077 Background: While targeted DNA-seq can detect clinically actionable fusions in tumor tissue samples, technical and analytical challenges may give rise to false negatives. RNA-based,…
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant…
PURPOSE With the advent of precision medicine, molecular tumor boards (MTBs) were established to interpret genomic results and guide decision making for targeted therapy in…
